Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of polypeptide, polypeptide derivative, pharmaceutically acceptable salt of polypeptide and pharmaceutical composition

The technology of a composition and a medicinal salt, which is applied in the field of medicine and pharmacy, can solve the problems of short plasma half-life, and achieve the effects of long plasma half-life, improving islet function and good stability.

Active Publication Date: 2021-04-06
SHENZHEN HIGHTIDE BIOPHARM
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is to provide a polypeptide for the short plasma half-life of INGAP-PP in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of polypeptide, polypeptide derivative, pharmaceutically acceptable salt of polypeptide and pharmaceutical composition
  • A kind of polypeptide, polypeptide derivative, pharmaceutically acceptable salt of polypeptide and pharmaceutical composition
  • A kind of polypeptide, polypeptide derivative, pharmaceutically acceptable salt of polypeptide and pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0128] Example 1 Production of Polypeptides

[0129] This example describes the production of polypeptides

[0130] All peptides used in this study were synthesized using 9-fluorenylmethyl chloroformate (Fmoc) solid-phase synthesis. Simply put: Dissolve a weighed amount of 2-chlorotrityl chloride resin (1.6mmol / g) in dichloromethane (DCM). For C-terminally amidated peptides of interest, use Rink amide resin instead of 2-chlorotrityl chloride resin. For coupling reactions in the presence of hydroxybenzotriazole (Sigma Chemicals, Inc., St. Louis, MO, USA) in dimethylformamide (DMF), preactivated Fmoc-amino acids were used. The entire synthesis process uses an excess of amino acids. Deprotection of the Fmoc group in 20% piperidine in DMF leads to chain extension reactions. When the chain extension reaction was completed, the Fmoc protecting group was removed from the N-terminus of the polypeptide using DMF containing 25% piperidine, and then washed four times with DMF solutio...

Embodiment 2

[0134] Example 2 The promoting effect of polypeptide on cell proliferation

[0135] This example describes the effects of polypeptides on the growth of pancreatic cells.

[0136] Cell proliferation was measured by bromodeoxyuridine (BrdU)-labeled ELISA. Briefly, a rat pancreatic ductal ARIP cell (ATCC (American Type Culture Collection), Manassas, VA, USA) was cultured in 10% fetal bovine serum (FBS, Fetal Bovine Serum, Thermo Fisher Inc., Waltham, MA, USA), in F-12K medium (GIBCO-BRL, Gaithersburg, MD, USA) with 100 μg / ml streptomycin and 100 μg / ml penicillin. ARIP cells were inoculated into 96-well culture plates at a density of 8000 or 0 (blank control) cells / well, and 50 μl of cell culture medium was added to culture overnight for use in experiments. The next day, use serum-free medium to replace the original medium, and 50 μl of serum-free cell culture medium containing a series of concentrations of the test polypeptide (final concentrations are 10 μM, 5 μM, 1 μM, 500 nM...

Embodiment 3

[0142] Example 3 Peptide Stability Experiment

[0143] This example describes stability experiments of peptides under various conditions.

[0144]Accurately weigh a certain amount of the selected peptide, dissolve it in distilled water to a concentration of 5 mg / mL, and use it as a stock solution to examine the stability of the peptide in the culture medium. Use F-12K medium (GIBCO-BRL, Gaithersburg, MD, USA) to dilute the stock solution to 0.25 mg / mL as a working solution. Transfer each 100 µL of working solution to a separate vial. After the vials were placed in a 37°C incubator for 0, 24, 48 and 72 hours, quantitative analysis was performed using HPLC.

[0145] figure 2 and Table 6 shows the stability of the compounds in the medium. figure 2 In particular, a comparison of the stability in culture medium of INGAP-PP (peptide 1) and selected peptides, peptides 7 and 8 (see Table 2) is shown.

[0146] Table 6

[0147] polypeptide 0h 24h 48h 72h pepti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

In order to overcome the problems of short plasma half-life and low activity of the insulin-promoting polypeptide in the prior art, the present invention provides a polypeptide. At the same time, the invention also discloses derivatives, pharmaceutically acceptable salts and pharmaceutical compositions of the above polypeptides. The polypeptide provided by the invention has high stability in blood and long half-life.

Description

[0001] This application is based on, and claims priority from, an earlier PCT international application (application number PCT / CN2013 / 072771) filed on March 15, 2013, the entire content of which is hereby incorporated by reference into this application. technical field [0002] The present invention mainly relates to the fields of medicine and pharmacy, especially a polypeptide, derivatives of the polypeptide, pharmaceutically acceptable salts and pharmaceutical compositions. Background technique [0003] More than 300 million people worldwide suffer from and suffer from diabetes mellitus (DM). There are two main types of diabetes: type 1 diabetes (T1D) and type 2 diabetes (T2D). Type 1 diabetes is caused by the body's inability to produce insulin and the patient needs to be treated with daily insulin. Type 2 diabetes is caused by insulin resistance, which means that the body's cells cannot use insulin properly. At present, there are many proven and effective non-insulin t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/47A61K38/17A61P3/10C12N5/071C12N5/079
CPCA61K38/00C07K14/4733C07K14/474C12N5/0618C12N5/067C12N5/0676C12N2501/998
Inventor 刘利平白茹
Owner SHENZHEN HIGHTIDE BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com